Keratoconus is one of Dr. Pinelli’s main research interests.
This progressive disease creates bulging in several points of the cornea, inducing irregular astigmatism often associated with myopia. Over time, the myopia becomes increasingly difficult to manage, due to the impossibility of correcting the distorted vision with contact lenses or glasses.
The final frontier for the treatment of keratoconus involves halting disease progression, which in most patients would lead inexorably to corneal transplantation.
This objective was achieved by strengthening the corneal structure by means of osmotic transepithelial corneal crosslinking, which creates new collagen bonds within the corneal stroma. This means that, although keratoconus cannot recede or heal, the corneal displacement produced by the cones on the corneal surface is contained and the evolution of the disease is blocked, preventing the much-feared corneal transplant.
Crosslinking is made possible by the synergistic action of ultraviolet light – emitted at determined and well-calibrated frequency conditions – with ParaCel®, an eye-drop formula patented by Dr. Pinelli based on riboflavin (vitamin B2), which has been shown to penetrate the cornea without the needing to remove it as a result of its high osmolarity.
The corneal curvature imprinted by the PiXL treatment performed with the newKXL II system through the synergy between riboflavin and high intensity ultraviolet light is the only non-surgical correction of mild myopia.